Author: oqorypharma - OQORY, INC

Posts by oqorypharma

10 Feb

Oqory to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 11, 2025
Posted by oqorypharma
Leave a comment

SAN DIEGO, Calif., Feb. 10, 2025 –- Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Michael King, Chief Executive Officer,...

10 Sep

Morgan Stanley 20th Annual Global Healthcare Conference

September 10, 2024
Posted by oqorypharma
Leave a comment

- About the "Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System" Panel Participants - View Presentation - View Poster

10 Sep

KOL Event: New Horizons for the Treatment of Non-Small Cell Lung Cancer

September 10, 2024
Posted by oqorypharma
Leave a comment

Supporting Materials - About the "Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System" Panel Participants - View Presentation - View Poster

10 Sep

KOL Event: Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System Click here

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...

10 Sep

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...

10 Sep

Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...

10 Sep

Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...

10 Sep

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...

10 Sep

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...

10 Sep

Report of Organizational Actions Affecting Basis of Securities

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...

12 3

9380 Judicial Drive
San Diego, CA 92121

info@oqory.com

Investors
investors@oqory.com

Business Development
business@oqory.com

Media Requests
mediarelations@oqory.com

Home

About

Science

Investors

News

Contact

© 2025 Oqory, Inc. All rights reserved. Terms of Use | Forward Looking Statements | Privacy Policy | Cookie Policy